SAR analysis, based on the final evidence that 28 of 32 HTPD compounds are protective versus 10 out of 1,008 nonheterocyclics suggests that the HTPD backbone's activity is highly significant within the intact screening set.
← all excerpts
Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology.
1
—
—